LyophilizedPowderLyophilizedPowder
Thisproductisfreezedried.Allwatermoleculeshavebeenremoved.
AntigenIncl.AntigenIncl.
ThisantibodyisshippedwithitsantigenFREEofcharge!
ShippedatRoomTemp.ShippedatRoomTemp.
Thislyophilizedproductisshippedatroomtemperature.Pleaseseeitscertificateofanalysisforfurtherstorageinstructions.
Type:Polyclonal
Source:Rabbit
Reactivity:h
ImmunogenPeptideCGQPKEGKNHSQG,correspondingtoaminoacidresidues146-158ofhumanadenosine A2A receptor(AccessionP29274).Extracellular,2ndloop.
Accession(Uniprot)NumberP29274
GeneID135
PeptideconfirmationConfirmedbyaminoacidanalysisandmassspectrometry.
HomologyHumanonly.
PurityAffinitypurifiedonimmobilizedantigen.
FormulationLyophilizedpowder.Reconstitutedantibodycontainsphosphatebufferedsaline(PBS),pH7.4,1%BSA,0.05%NaN3.
SpecificityWillnotrecognizeratormousesamples.
LabelFluoresceinisothiocyanate(FITC).
StoragebeforereconstitutionTheantibodyshipsasalyophilizedpowderatroomtemperature.Uponarrival,itshouldbestoredat-20°C.
Reconstitution50µldoubledistilledwater(DDW).
Antibodyconcentrationafterreconstitution1mg/ml.
StorageafterreconstitutionThereconstitutedsolutioncanbestoredat4°C,protectedfromthelight,forupto1week.Forlongerperiods,smallaliquotsshouldbestoredat-20°C.Avoidmultiplefreezingandthawing.Centrifugeallantibodypreparationsbeforeuse(10000×g5min).
ControlantigenstoragebeforereconstitutionLyophilizedpowdercanbestoredintactatroomtemperaturefortwoweeks.Forlongerperiods,itshouldbestoredat-20°C.
Controlantigenreconstitution100µldoubledistilledwater(DDW).
Controlantigenstorageafterreconstitution-20°C.
PreadsorptionControl1µgpeptideper1µgantibody.
StandardqualitycontrolofeachlotWesternblotanalysis(unlabeledantibody,#AAR-007),anddirectflowcytometry(labeledantibody).
Applications:fc
Mayalsoworkin:ic,lci
DirectflowcytometryDirectflowcytometryofliveintacthumanTHP-1monocyticleukemiacells:
___ Cells.
___Cells+rabbitIgGisotypecontrol-FITC.
___ Cells+Anti-HumanAdenosineA2A Receptor(extracellular)-FITCAntibody (#AAR-007-F),(2.5µg).
DirectflowcytometryofliveintacthumanJurkatT-cellleukemiacells:
___ Cells.
___Cells+rabbitIgGisotypecontrol-FITC.
___ Cells+Anti-HumanAdenosineA2A Receptor(extracellular)-FITC Antibody (#AAR-007-F),(2.5µg).
ReferencesOkusa,M.D.(2002)Am.J.Physiol.282,F10.
Fredholm,B.B.etal.(2001)Pharmacol.Rev.53,527.
Nakata,H.(1989)J.Biol.Chem.264,16545.
Cunha,R.A.(2001)
NeuRochem.Int.38,107.
Fredholm,B.B.etal.(2000)Naunyn-SchmiedebergsArch.Pharmacol.362,364.
Canals,M.etal.(2005)J.Neurochem.92,337.
Ohta,A.andSitkovsky,M.(2001)Nature414,916.
Ohta,A.etal.(2006)Proc.Natl.Acad.Sci.103,13132.
ScientificbackgroundAdenosineisanendogenousnucleosidegeneratedlocallyintissuesunderconditionsofhypoxia,ischemia,orinflammation.Itmodulatesavarietyofphysiologicalfunctionsinmanytissuesincludingthebrainandheart1,2. Adenosineexertsitsactionsviafourspecificadenosinereceptors(alsonamedP1purinergicreceptors): AdenosineA1 Receptor (A1AR),AdenosineA2A Receptor(A2AAR), AdenosineA2B Receptor (A2BAR),and AdenosineA3 Receptor (A3AR).Allareintegralmembraneproteinsandaremembersofthe Gprotein-coupled receptorsuperfamily.Theyshareacommonstructureofsevenputativetransmembranedomains,anextracellular-NH2 terminus,cytoplasmic-COOHterminus,andathirdintracellularloopimportantforbindingGproteins.1-3 Theadenosinereceptorscanbedistinguishedonthebasisoftheirdifferentialselectivityforadenosineanalogs1-3.
Adenosinereceptorscontrolneurotransmitterreleasethroughthe facilitatory A2AARandtheinhibitoryA1AR.4 A2AARandA1ARarethemajoradenosinereceptorsubtypesexpressedinthecentralnervoussystem(CNS).A2AARismainlyexpressedinthestriatumonGABAergicstriatopallidalneurons,whileA1ARiswidelydistributedthroughouttheCNS5,6.
A2AARwassuggestedtoplayacriticalroleinattenuationofsystemicinflammatoryresponsesandpreventionofextensivetissuedamage.7 ItwassuggestedthatextracellularadenosinethataccumulatesininflamedanddamagedtissuemayactivatetheA2AARexpressedinimmunecellsleADIngtotermination/inhibitionoftheimmuneresponse.7 ItwasfurthersuggestedthatthissamemechanismmayprotecttumorsfromantitumorTcellsthroughanimmunosuppressivesignalgeneratedbytheactivationofA2AARonTcellsbyextracellularadenosineproducedfromhypoxiccanceroustissues8.
LyophilizedPowderControlAntigenIncluded
Lastupdate:24/03/2019
Anti-HumanAdenosineA2A Receptor(extracellular)Antibody (#AAR-007)isahighlyspecificantibodydirectedagainstanepitopeofhumanprotein.Theantibodycanbeusedinwesternblotandlivecellflowcytometryapplications.IthasbeendesignedtorecognizeA2aRfromhumansamplesonly.Theantibodywillnotrecognizethereceptorfrommouseorratsamples.
Anti-HumanAdenosineA2A Receptor(extracellular)-FITC Antibody (#AAR-007-F)is directlyconjugatedtofluoresceinisothiocyanate(FITC). The antibodycanbeusedinimmunofluorescentapplicationssuchasdirectlivecellflowcytometry.
Forresearchpurposesonly,notforhumanuse
DirectflowcytometryDirectflowcytometryofliveintacthumanTHP-1monocyticleukemiacells:
___ Cells.
___Cells+rabbitIgGisotypecontrol-FITC.
___ Cells+Anti-HumanAdenosineA2A Receptor(extracellular)-FITCAntibody (#AAR-007-F),(2.5µg).
DirectflowcytometryofliveintacthumanJurkatT-cellleukemiacells:
___ Cells.
___Cells+rabbitIgGisotypecontrol-FITC.
___ Cells+Anti-HumanAdenosineA2A Receptor(extracellular)-FITC Antibody (#AAR-007-F),(2.5µg).
ReferencesOkusa,M.D.(2002)Am.J.Physiol.282,F10.
Fredholm,B.B.etal.(2001)Pharmacol.Rev.53,527.
Nakata,H.(1989)J.Biol.Chem.264,16545.
Cunha,R.A.(2001)Neurochem.Int.38,107.
Fredholm,B.B.etal.(2000)Naunyn-SchmiedebergsArch.Pharmacol.362,364.
Canals,M.etal.(2005)J.Neurochem.92,337.
Ohta,A.andSitkovsky,M.(2001)Nature414,916.
Ohta,A.etal.(2006)Proc.Natl.Acad.Sci.103,13132.